Refractory or Relapsed Multiple Myeloma: Clinical Trials

1 trial for Refractory or Relapsed Multiple Myeloma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Active not recruiting 1

Follow Refractory or Relapsed Multiple Myeloma: new trials by email Literature Review of Refractory or Relapsed Multiple Myeloma trials Research Report on Refractory or Relapsed Multiple Myeloma

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
CT-P44(Daratumumab), Darzalex Faspro(Daratumumab) - Refractory or Relapsed Multiple Myeloma
Phase 3Active not recruitingCelltrion4732025-08-122026-10-27

Narrower conditions

Multiple Myeloma (1)

Broader conditions

Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms, Plasma Cell (1)  ·  Paraproteinemias (1)  ·  Vascular Diseases (1)

Sponsors

Celltrion (1)

Countries

Taiwan (1)